849674-11-9

Usage

Uses

Used in Organic Synthesis:
(3R,4S)-tert-Butyl 3-(bis(4-Methoxyphenyl)(phenyl)Methoxy)-4-((Methylsulfonyl)oxy)pyrrolidine-1-carboxylate is used as a key intermediate in organic synthesis for the creation of various complex organic molecules. Its unique structural features, including the tert-butyl and methoxyphenyl groups, make it a versatile building block for constructing a wide range of chemical entities.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, (3R,4S)-tert-Butyl 3-(bis(4-Methoxyphenyl)(phenyl)Methoxy)-4-((Methylsulfonyl)oxy)pyrrolidine-1-carboxylate is employed as a valuable compound for drug development. Its specific structural elements, such as the methylsulfonyl group, may contribute to its potential biological activity, making it a promising candidate for the design and synthesis of new pharmaceutical agents.
Used in Chemical Research:
(3R,4S)-tert-Butyl 3-(bis(4-Methoxyphenyl)(phenyl)Methoxy)-4-((Methylsulfonyl)oxy)pyrrolidine-1-carboxylate is also utilized in chemical research to explore its properties and reactivity. Understanding how (3R,4S)-tert-Butyl 3-(bis(4-Methoxyphenyl)(phenyl)Methoxy)-4-((Methylsulfonyl)oxy)pyrrolidine-1-carboxylate interacts with other chemicals can provide insights into its potential applications and help in the development of new synthetic methods and techniques.
Used in Pharmaceutical Research:
In the pharmaceutical industry, (3R,4S)-tert-Butyl 3-(bis(4-Methoxyphenyl)(phenyl)Methoxy)-4-((Methylsulfonyl)oxy)pyrrolidine-1-carboxylate is used as a starting material for the synthesis of new drug candidates. Its unique structural features and potential biological activity make it an attractive compound for the development of novel therapeutic agents with improved efficacy and selectivity.
Overall, the diverse applications of (3R,4S)-tert-Butyl 3-(bis(4-Methoxyphenyl)(phenyl)Methoxy)-4-((Methylsulfonyl)oxy)pyrrolidine-1-carboxylate across various industries highlight its importance and potential in the realm of chemical and pharmaceutical research.

Upstream product

• 108-05-4 vinyl acetate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 141-78-6 ethyl acetate 
• 73286-70-1 N-(tert-butoxycarbonyl)-3-pyrroline 
• 114214-49-2 1-tert-butoxycarbonyl-3,4-epoxypyrrolidine 
• 100-59-4 phenylmagnesium chloride 
• 100-58-3 phenylmagnesium bromide 
• 114214-49-2 rac-tert-butyl (1R,5S)-6-oxa-3-azabicyclo[3.1.0]hexane-3-carboxylate 
• 108-86-1 bromobenzene 

Downstream Products

• 952343-56-5 (-)-(3R,4S)-tert-butyl 3-hydroxy-4-phenylpyrrolidine-1-carboxylate 
• 849672-36-2 (3R,4S)-3-({(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}oxy)-4-phenylpyrrolidine 
• 849671-88-1 2-amino-3-[(3R,4S)-3-({(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}oxy)-4-phenylpyrrolidin-1-yl]-3-oxopropan-1-ol 
• 849671-89-2 4-{[(3R,4S)-3-({(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}oxy)-4-phenylpyrrolidin-1-yl]carbonyl}-1,3-oxazolidine-2-one 
• 1242166-68-2 C₁₀H₁₃NO 

Relevant academic research and scientific papers

HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6

The present disclosure relates to compounds capable of modulating the activity of NR2F6. The compounds of the disclosure may be used in methods for the prevention and/or the treatment of diseases and disorders associated with modulating NR2F6 activity.

Highly enantioselective organocatalytic oxidative kinetic resolution of secondary alcohols using chiral alkoxyamines as precatalysts: Catalyst structure, active species, and substrate scope

The development and characterization of enantioselective organocatalytic oxidative kinetic resolution (OKR) of racemic secondary alcohols using chiral alkoxyamines as precatalysts are described. A number of chiral alkoxyamines have been synthesized, and their structure-enantioselectivity correlation study in OKR has led us to identify a promising precatalyst, namely, 7-benzyl-3-n-butyl-4-oxa-5-azahomoadamantane, which affords various chiral aliphatic secondary alcohols (ee up to >99%, krel up to 296). In a mechanistic study, chlorine-containing oxoammonium species were identified as the active species generated in situ from the alkoxyamine precatalyst, and it was revealed that the chlorine atom is crucial for high reactivity and enantioselectivity. The present OKR is the first successful example applicable to various unactivated aliphatic secondary alcohols, including heterocyclic alcohols with high enantioselectivity, the synthetic application of which is demonstrated by the synthesis of a bioactive compound.

PYRROL-1 -YL BENZOIC ACID DERIVATES USEFUL AS MYC INHIBITORS

The present invention provides compounds of Formula (I-A), (I-B), and (I-C), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting Myc (e.g., c-Myc) activity. The p

Enzyme-catalyzed kinetic resolution of N-Boc-trans-3-hydroxy-4- phenylpyrrolidine

The first enzyme-catalyzed kinetic resolution of tert-butyl-3-hydroxy-4- phenylpyrrolidine-1-carboxylate is presented. Enzyme, solvent and temperature optimization resulted in a new resolution method with E = 40 enantioselectivity. The acetate derivative of the (+)-(3S,4R) enantiomer formed while the (-)-(3R,4S) isomer remained intact. Very good enantioselectivities (E > 200) were achieved in the enzyme-catalyzed alcoholysis of the racemic acetate in i-propanol and t-butanol where the (+)-(3S,4R) enantiomer was prepared in pure form (ee > 99.7%). Absolute configuration of the (-)-(3R,4S)-enantiomer was determined by single crystal X-ray diffraction method. [Figure not available: see fulltext.]

The discovery of potent, selective, and orally bioavailable hNK1 antagonists derived from pyrrolidine

SAR studies on amides, ureas, and vinylogous amides derived from pyrrolidine led to the discovery of several potent hNK1 antagonists. One particular vinylogous amide (45b) had excellent potency, selectivity, pharmacokinetic profile, and functio

PHENYL PYRROLIDINE ETHER TACHYKININ RECEPTOR ANTAGONISTS

The present invention is directed to certain phenyl pyrrolidine ether compounds which are useful as neurokinin-1 (NK-1) receptor antagonists, and inhibitors of tachykinin and in particular substance P. The invention is also concerned with pharmaceutical f